Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70194 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Laura K Lepenies und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty Heidelberg/Heidelberg University Hospital, Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Heide…. Hauptthemen laut MEDLINE: Cholinergic Antagonists, Dementia, Deprescriptions, Inappropriate Prescribing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research (BMBF), Bundesministerium für Bildung und Forschung.
Themen: Demenz
Abstract (Originalsprache)
Aim
Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline.
Methods
The AgeWell.de study, a multi‐centre, cluster‐randomized controlled study, was conducted in 123 German general practices between June 2018 and January 2022. The study included a multicomponent intervention programme for patients at increased risk of dementia, delivered over a 2‐year period. As part of the medication optimisation intervention, patient data and medication records were screened to identify medication risks and provide recommendations to general practitioners.
Results
In total, 808 patients with complete data were included in the present analysis (intervention group = 374, control group = 434). At baseline, 132 (16.8%) patients had at least one anticholinergic prescription. After 2 years, approximately one‐third of these patients no longer received drugs with anticholinergic effects. There were no significant differences between the intervention and control groups, with 67.6% and 72.1%, respectively, continuing to take drugs with anticholinergic effects ( P = 0.57). Patients reported anticholinergic symptoms more frequently when taking any medication (5.0% vs 33.8%), and even more so when taking drugs with anticholinergic effects (56.1%). Deprescribing of all drugs with anticholinergic effects was non‐significantly higher in patients who reported at least one anticholinergic symptom compared to patients without any anticholinergic symptoms (58.6% vs 54.1%).
Conclusion
The medication optimisation intervention did not entail significant differences in anticholinergic deprescribing between the groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty Heidelberg/Heidelberg University Hospital, Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Heidelberg, Germany.
- Medical Faculty Heidelberg/Heidelberg University Hospital, Cooperation Unit Clinical Pharmacy, Heidelberg University, Heidelberg, Germany.
- Institute of Social Medicine, Occupational Health and Public Health (ISAP), Leipzig University, Leipzig, Germany.
- Institute of General Practice, University of Kiel, Kiel, Germany.
- Institute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany.
- Institute of General Practice and Family Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
ORCID-Profile: Laura K Lepenies, Hanna M Seidling, David Czock
Förderung
- Federal Ministry of Education and Research (BMBF)
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Lepenies, L. K., Seidling, H. M., Pabst, A., Luppa, M., Döhring, J., Williamson, M., Frese, T., Gensichen, J., Hoffmann, W., Kaduszkiewicz, H., König, H. H., Thyrian, J. R., Wiese, B., Riedel-Heller, S. G., & Czock, D. (2025). Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70194
Vancouver
Lepenies LK, Seidling HM, Pabst A, Luppa M, Döhring J, Williamson M, et al. Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70194
BibTeX
@article{Lepenies2025,
author = {Lepenies, Laura K and Seidling, Hanna M and Pabst, Alexander and Luppa, Melanie and Döhring, Juliane and Williamson, Martin and Frese, Thomas and Gensichen, Jochen and Hoffmann, Wolfgang and Kaduszkiewicz, Hanna and König, Hans-Helmut and Thyrian, Jochen René and Wiese, Birgitt and Riedel-Heller, Steffi G and Czock, David},
title = {Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70194}
}
EUVIMED